Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy Planning, Computer-Assisted | 119 | 2024 | 1660 | 11.490 |
Why?
|
Radiotherapy, Intensity-Modulated | 36 | 2024 | 801 | 5.600 |
Why?
|
Radiotherapy Dosage | 97 | 2024 | 2897 | 3.760 |
Why?
|
Radiotherapy, Conformal | 31 | 2011 | 549 | 3.740 |
Why?
|
Radiometry | 29 | 2013 | 813 | 3.280 |
Why?
|
Radiation Oncology | 12 | 2024 | 563 | 2.650 |
Why?
|
Radiotherapy | 17 | 2023 | 1505 | 1.940 |
Why?
|
Algorithms | 61 | 2024 | 13967 | 1.870 |
Why?
|
Phantoms, Imaging | 34 | 2024 | 2510 | 1.670 |
Why?
|
Health Physics | 5 | 2024 | 30 | 1.550 |
Why?
|
Radiation Pneumonitis | 2 | 2022 | 102 | 1.350 |
Why?
|
Radiotherapy, Computer-Assisted | 8 | 2011 | 90 | 1.300 |
Why?
|
Protons | 16 | 2023 | 1113 | 1.250 |
Why?
|
Radiotherapy, High-Energy | 11 | 2009 | 228 | 1.220 |
Why?
|
Brain Neoplasms | 14 | 2024 | 8984 | 1.150 |
Why?
|
Neoplasms | 29 | 2023 | 22066 | 1.140 |
Why?
|
Models, Biological | 21 | 2019 | 9468 | 0.940 |
Why?
|
Models, Theoretical | 18 | 2021 | 3561 | 0.920 |
Why?
|
Positron-Emission Tomography | 17 | 2020 | 6457 | 0.910 |
Why?
|
Radiation Injuries | 7 | 2024 | 1183 | 0.910 |
Why?
|
Scattering, Radiation | 14 | 2016 | 488 | 0.890 |
Why?
|
Photons | 18 | 2018 | 581 | 0.860 |
Why?
|
Chordoma | 5 | 2023 | 346 | 0.860 |
Why?
|
Motion | 10 | 2012 | 779 | 0.850 |
Why?
|
Salaries and Fringe Benefits | 1 | 2024 | 258 | 0.810 |
Why?
|
Liver Neoplasms | 8 | 2021 | 4317 | 0.780 |
Why?
|
Muscle Fibers, Skeletal | 2 | 2024 | 543 | 0.770 |
Why?
|
Monte Carlo Method | 20 | 2024 | 1256 | 0.750 |
Why?
|
Organs at Risk | 5 | 2022 | 358 | 0.730 |
Why?
|
Uncertainty | 8 | 2022 | 754 | 0.720 |
Why?
|
Lung Neoplasms | 18 | 2024 | 13249 | 0.680 |
Why?
|
Four-Dimensional Computed Tomography | 2 | 2011 | 144 | 0.680 |
Why?
|
Glioblastoma | 4 | 2023 | 3482 | 0.660 |
Why?
|
Diffusion Tensor Imaging | 3 | 2024 | 2383 | 0.650 |
Why?
|
Physics | 5 | 2021 | 90 | 0.620 |
Why?
|
Tomography, X-Ray Computed | 27 | 2024 | 20484 | 0.580 |
Why?
|
Glioma | 3 | 2024 | 3420 | 0.560 |
Why?
|
Tumor Burden | 4 | 2022 | 1897 | 0.560 |
Why?
|
Head and Neck Neoplasms | 16 | 2024 | 2880 | 0.560 |
Why?
|
Radiation Dosage | 7 | 2018 | 1957 | 0.550 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2024 | 5248 | 0.510 |
Why?
|
Movement | 10 | 2015 | 1474 | 0.510 |
Why?
|
Spinal Neoplasms | 6 | 2013 | 716 | 0.510 |
Why?
|
Probability | 8 | 2022 | 2476 | 0.500 |
Why?
|
Dose-Response Relationship, Radiation | 13 | 2011 | 881 | 0.490 |
Why?
|
Technology, Radiologic | 4 | 2013 | 160 | 0.490 |
Why?
|
Humans | 153 | 2024 | 760261 | 0.450 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2024 | 3335 | 0.430 |
Why?
|
Particle Accelerators | 10 | 2021 | 174 | 0.430 |
Why?
|
Lung Injury | 1 | 2018 | 424 | 0.430 |
Why?
|
Computer Simulation | 14 | 2012 | 6210 | 0.400 |
Why?
|
Image Processing, Computer-Assisted | 16 | 2024 | 8945 | 0.380 |
Why?
|
Mathematics | 6 | 2019 | 708 | 0.380 |
Why?
|
Reproducibility of Results | 27 | 2024 | 20048 | 0.370 |
Why?
|
Gadolinium DTPA | 1 | 2014 | 826 | 0.370 |
Why?
|
Biomedical Technology | 1 | 2013 | 211 | 0.360 |
Why?
|
Software | 8 | 2012 | 4420 | 0.350 |
Why?
|
Sensitivity and Specificity | 19 | 2024 | 14656 | 0.340 |
Why?
|
Relative Biological Effectiveness | 10 | 2018 | 312 | 0.340 |
Why?
|
Diffusion of Innovation | 1 | 2013 | 730 | 0.310 |
Why?
|
Database Management Systems | 1 | 2009 | 258 | 0.300 |
Why?
|
Hepatocytes | 1 | 2014 | 1228 | 0.290 |
Why?
|
Biophysical Phenomena | 9 | 2003 | 320 | 0.280 |
Why?
|
Prostatic Neoplasms | 16 | 2022 | 11341 | 0.280 |
Why?
|
Body Burden | 8 | 2009 | 158 | 0.280 |
Why?
|
Models, Statistical | 13 | 2022 | 5073 | 0.270 |
Why?
|
Quality Assurance, Health Care | 2 | 2016 | 2178 | 0.270 |
Why?
|
Biophysics | 9 | 2003 | 380 | 0.270 |
Why?
|
Electrons | 3 | 2008 | 264 | 0.270 |
Why?
|
Therapy, Computer-Assisted | 1 | 2008 | 267 | 0.270 |
Why?
|
Synchrotrons | 3 | 2017 | 39 | 0.260 |
Why?
|
Cerebellar Neoplasms | 1 | 2010 | 585 | 0.250 |
Why?
|
Respiratory Mechanics | 2 | 2008 | 698 | 0.250 |
Why?
|
Respiration | 6 | 2010 | 1648 | 0.240 |
Why?
|
Medulloblastoma | 1 | 2010 | 677 | 0.240 |
Why?
|
Visible Human Projects | 1 | 2024 | 12 | 0.240 |
Why?
|
Calibration | 6 | 2023 | 816 | 0.240 |
Why?
|
Normal Distribution | 5 | 2012 | 273 | 0.230 |
Why?
|
Spine | 1 | 2010 | 1111 | 0.220 |
Why?
|
Pancreatic Neoplasms | 3 | 2011 | 5333 | 0.210 |
Why?
|
Linear Energy Transfer | 1 | 2003 | 152 | 0.210 |
Why?
|
Linear Models | 2 | 2018 | 5876 | 0.210 |
Why?
|
Career Mobility | 1 | 2024 | 258 | 0.200 |
Why?
|
Sarcoma | 2 | 2022 | 1786 | 0.200 |
Why?
|
Technology Assessment, Biomedical | 1 | 2004 | 305 | 0.190 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2007 | 0.190 |
Why?
|
Feasibility Studies | 7 | 2022 | 5201 | 0.180 |
Why?
|
Job Satisfaction | 1 | 2024 | 539 | 0.180 |
Why?
|
Anisotropy | 1 | 2024 | 1278 | 0.180 |
Why?
|
Time Factors | 15 | 2018 | 40133 | 0.170 |
Why?
|
Prostheses and Implants | 1 | 2007 | 1272 | 0.170 |
Why?
|
Bone Marrow | 1 | 2010 | 2918 | 0.170 |
Why?
|
X-Ray Therapy | 1 | 1999 | 8 | 0.170 |
Why?
|
Magnetic Resonance Imaging | 10 | 2023 | 36247 | 0.170 |
Why?
|
Skull Neoplasms | 2 | 2013 | 173 | 0.170 |
Why?
|
Entrepreneurship | 1 | 2019 | 23 | 0.170 |
Why?
|
Spectrometry, Gamma | 1 | 2018 | 5 | 0.160 |
Why?
|
Lymphocyte Count | 1 | 2021 | 780 | 0.160 |
Why?
|
Muscles | 1 | 2023 | 1581 | 0.150 |
Why?
|
Skull Base Neoplasms | 1 | 2021 | 269 | 0.150 |
Why?
|
Radiobiology | 1 | 2018 | 89 | 0.150 |
Why?
|
Radiation Protection | 4 | 2013 | 425 | 0.140 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2004 | 1215 | 0.140 |
Why?
|
Databases, Factual | 2 | 2009 | 8018 | 0.140 |
Why?
|
Subtraction Technique | 3 | 2009 | 510 | 0.130 |
Why?
|
Organizational Innovation | 1 | 2019 | 536 | 0.130 |
Why?
|
Patient Positioning | 2 | 2015 | 327 | 0.130 |
Why?
|
Oxygen Radioisotopes | 1 | 2015 | 75 | 0.130 |
Why?
|
Markov Chains | 1 | 2019 | 971 | 0.130 |
Why?
|
Bayes Theorem | 1 | 2022 | 2325 | 0.120 |
Why?
|
Rotation | 2 | 2010 | 514 | 0.110 |
Why?
|
Academic Medical Centers | 1 | 2024 | 2753 | 0.110 |
Why?
|
Radiation Tolerance | 3 | 2014 | 480 | 0.110 |
Why?
|
Radiosurgery | 4 | 2015 | 1343 | 0.110 |
Why?
|
Image Enhancement | 1 | 2024 | 2877 | 0.110 |
Why?
|
Scintillation Counting | 1 | 2013 | 36 | 0.110 |
Why?
|
Patient Care Planning | 1 | 1999 | 909 | 0.110 |
Why?
|
Retrospective Studies | 7 | 2022 | 80301 | 0.110 |
Why?
|
Equipment Design | 4 | 2013 | 3520 | 0.110 |
Why?
|
Cholangiocarcinoma | 1 | 2018 | 547 | 0.100 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 425 | 0.100 |
Why?
|
Stereotaxic Techniques | 5 | 2002 | 549 | 0.100 |
Why?
|
Gamma Rays | 1 | 2013 | 317 | 0.100 |
Why?
|
Quality Control | 3 | 2006 | 827 | 0.100 |
Why?
|
Artifacts | 3 | 2007 | 1893 | 0.100 |
Why?
|
Male | 32 | 2024 | 359413 | 0.100 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2016 | 470 | 0.100 |
Why?
|
X-Rays | 3 | 2002 | 307 | 0.100 |
Why?
|
Models, Organizational | 1 | 2015 | 545 | 0.100 |
Why?
|
Forecasting | 3 | 2013 | 2931 | 0.100 |
Why?
|
Hospitals, General | 1 | 2015 | 795 | 0.090 |
Why?
|
Chondrosarcoma | 1 | 2013 | 296 | 0.090 |
Why?
|
Risk | 1 | 2023 | 9629 | 0.090 |
Why?
|
Clinical Protocols | 1 | 2016 | 1439 | 0.090 |
Why?
|
Rectum | 5 | 2007 | 896 | 0.090 |
Why?
|
Esophagus | 1 | 2016 | 1023 | 0.090 |
Why?
|
Swine | 3 | 2024 | 5902 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9274 | 0.080 |
Why?
|
Cyclotrons | 1 | 2008 | 30 | 0.080 |
Why?
|
International Cooperation | 1 | 2015 | 1436 | 0.080 |
Why?
|
Attitude | 1 | 2013 | 777 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3770 | 0.080 |
Why?
|
Thigh | 2 | 2022 | 239 | 0.070 |
Why?
|
Stochastic Processes | 1 | 2009 | 354 | 0.070 |
Why?
|
Medical Informatics | 1 | 2015 | 733 | 0.070 |
Why?
|
Carbon Isotopes | 1 | 2008 | 461 | 0.070 |
Why?
|
Water | 4 | 2022 | 1402 | 0.070 |
Why?
|
Hemangiopericytoma | 1 | 2007 | 71 | 0.070 |
Why?
|
Lung | 6 | 2024 | 9989 | 0.070 |
Why?
|
Fourier Analysis | 1 | 2008 | 438 | 0.070 |
Why?
|
Eye Neoplasms | 3 | 2011 | 306 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2001 | 3526 | 0.070 |
Why?
|
Plastics | 1 | 2007 | 115 | 0.070 |
Why?
|
Tomography | 1 | 2008 | 411 | 0.070 |
Why?
|
Information Dissemination | 1 | 2015 | 1132 | 0.070 |
Why?
|
Research | 1 | 2015 | 1973 | 0.070 |
Why?
|
Risk Assessment | 3 | 2017 | 24086 | 0.070 |
Why?
|
Insurance Coverage | 1 | 2017 | 1939 | 0.070 |
Why?
|
Computing Methodologies | 1 | 2005 | 17 | 0.060 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2018 | 2297 | 0.060 |
Why?
|
Filtration | 1 | 2006 | 229 | 0.060 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2011 | 286 | 0.060 |
Why?
|
Insurance, Health | 1 | 2017 | 2500 | 0.060 |
Why?
|
Mediastinal Neoplasms | 2 | 1999 | 402 | 0.060 |
Why?
|
Ependymoma | 1 | 2008 | 320 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2007 | 1790 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5507 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2017 | 3598 | 0.060 |
Why?
|
Safety | 1 | 2009 | 1149 | 0.060 |
Why?
|
Biotechnology | 1 | 2006 | 281 | 0.060 |
Why?
|
Consensus | 2 | 2023 | 3106 | 0.060 |
Why?
|
Motivation | 1 | 2013 | 1990 | 0.060 |
Why?
|
Female | 13 | 2024 | 391011 | 0.050 |
Why?
|
Ions | 1 | 2003 | 261 | 0.050 |
Why?
|
Ethmoid Sinus | 1 | 2002 | 57 | 0.050 |
Why?
|
Internet | 1 | 2015 | 3074 | 0.050 |
Why?
|
Equipment Failure Analysis | 1 | 2005 | 848 | 0.050 |
Why?
|
Massachusetts | 1 | 2015 | 8805 | 0.050 |
Why?
|
Internship and Residency | 1 | 2022 | 5867 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4637 | 0.050 |
Why?
|
Metals | 1 | 2007 | 736 | 0.050 |
Why?
|
Benchmarking | 1 | 2008 | 1043 | 0.050 |
Why?
|
Esophageal Neoplasms | 1 | 2011 | 1651 | 0.050 |
Why?
|
Radiography | 4 | 2012 | 6965 | 0.050 |
Why?
|
Brain Stem | 2 | 2012 | 857 | 0.050 |
Why?
|
Brain | 2 | 2024 | 26912 | 0.050 |
Why?
|
Spectrum Analysis | 1 | 2022 | 453 | 0.040 |
Why?
|
Adenocarcinoma | 4 | 2003 | 6310 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10183 | 0.040 |
Why?
|
Spinal Cord | 2 | 2007 | 1817 | 0.040 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2002 | 241 | 0.040 |
Why?
|
Medicine | 1 | 2008 | 943 | 0.040 |
Why?
|
Meningioma | 2 | 2007 | 1220 | 0.040 |
Why?
|
Carbon | 1 | 2003 | 669 | 0.040 |
Why?
|
Electronics | 1 | 2001 | 317 | 0.040 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 4923 | 0.040 |
Why?
|
Reference Standards | 1 | 2003 | 1004 | 0.040 |
Why?
|
Aged | 8 | 2018 | 168995 | 0.040 |
Why?
|
Statistics as Topic | 1 | 2006 | 2363 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4590 | 0.040 |
Why?
|
Online Systems | 1 | 2020 | 181 | 0.040 |
Why?
|
Accreditation | 1 | 2022 | 477 | 0.040 |
Why?
|
Biomedical Research | 1 | 2015 | 3421 | 0.040 |
Why?
|
Adult | 6 | 2018 | 219847 | 0.040 |
Why?
|
Middle Aged | 14 | 2018 | 220175 | 0.040 |
Why?
|
Pleural Neoplasms | 1 | 2003 | 609 | 0.040 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
Computer Systems | 2 | 2008 | 470 | 0.040 |
Why?
|
User-Computer Interface | 2 | 2008 | 1402 | 0.040 |
Why?
|
Health Facilities | 1 | 2022 | 578 | 0.040 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2557 | 0.040 |
Why?
|
Mesothelioma | 1 | 2003 | 806 | 0.040 |
Why?
|
Health Care Sector | 1 | 2019 | 196 | 0.040 |
Why?
|
Lymphocyte Subsets | 1 | 2018 | 310 | 0.040 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 305 | 0.030 |
Why?
|
Choroid Neoplasms | 1 | 1998 | 177 | 0.030 |
Why?
|
Head | 2 | 1993 | 922 | 0.030 |
Why?
|
Neurilemmoma | 2 | 1999 | 523 | 0.030 |
Why?
|
Societies, Medical | 1 | 2008 | 3903 | 0.030 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 1997 | 136 | 0.030 |
Why?
|
Animals | 6 | 2024 | 167940 | 0.030 |
Why?
|
Tomography, Emission-Computed | 1 | 1999 | 1121 | 0.030 |
Why?
|
Prostate | 2 | 2022 | 1793 | 0.030 |
Why?
|
Dogs | 1 | 2020 | 3843 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2011 | 4361 | 0.030 |
Why?
|
Workflow | 1 | 2020 | 851 | 0.030 |
Why?
|
Urinary Bladder | 2 | 2007 | 1166 | 0.030 |
Why?
|
Biochemical Phenomena | 1 | 2015 | 58 | 0.030 |
Why?
|
Bile Duct Neoplasms | 1 | 2000 | 600 | 0.030 |
Why?
|
Mathematical Computing | 1 | 1994 | 143 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 1997 | 391 | 0.030 |
Why?
|
Background Radiation | 1 | 2013 | 2 | 0.030 |
Why?
|
Combined Modality Therapy | 3 | 2019 | 8551 | 0.030 |
Why?
|
Commerce | 1 | 2019 | 604 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2018 | 64947 | 0.030 |
Why?
|
Permeability | 1 | 2015 | 719 | 0.030 |
Why?
|
Models, Structural | 1 | 1993 | 341 | 0.030 |
Why?
|
Splenic Neoplasms | 1 | 2003 | 96 | 0.030 |
Why?
|
Automation | 1 | 2014 | 581 | 0.020 |
Why?
|
Prostatectomy | 1 | 2021 | 1956 | 0.020 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2022 | 2776 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2359 | 0.020 |
Why?
|
Pelvis | 1 | 1994 | 743 | 0.020 |
Why?
|
Rectal Neoplasms | 1 | 1998 | 1151 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2204 | 0.020 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2011 | 262 | 0.020 |
Why?
|
Abdominal Neoplasms | 1 | 2010 | 286 | 0.020 |
Why?
|
Rabbits | 1 | 2015 | 4773 | 0.020 |
Why?
|
Anatomy, Regional | 1 | 2007 | 4 | 0.020 |
Why?
|
Sacrum | 1 | 2010 | 281 | 0.020 |
Why?
|
Work Simplification | 1 | 2007 | 8 | 0.020 |
Why?
|
Pilot Projects | 2 | 2017 | 8553 | 0.020 |
Why?
|
Aged, 80 and over | 4 | 2018 | 58947 | 0.020 |
Why?
|
Young Adult | 2 | 2013 | 58673 | 0.020 |
Why?
|
Skull | 1 | 2012 | 815 | 0.020 |
Why?
|
Neck | 1 | 1992 | 730 | 0.020 |
Why?
|
Curriculum | 1 | 2020 | 3722 | 0.020 |
Why?
|
Organ Specificity | 2 | 2003 | 1955 | 0.020 |
Why?
|
Models, Chemical | 1 | 2008 | 614 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4355 | 0.020 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2005 | 119 | 0.020 |
Why?
|
Surface Properties | 1 | 2008 | 1158 | 0.020 |
Why?
|
Neoplasm Staging | 3 | 2007 | 11141 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4554 | 0.010 |
Why?
|
Sample Size | 1 | 2007 | 840 | 0.010 |
Why?
|
Systems Integration | 1 | 2006 | 426 | 0.010 |
Why?
|
Maximum Allowable Concentration | 1 | 2003 | 63 | 0.010 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39254 | 0.010 |
Why?
|
Adolescent | 2 | 2010 | 87747 | 0.010 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2006 | 549 | 0.010 |
Why?
|
Treatment Failure | 1 | 2008 | 2646 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2003 | 4024 | 0.010 |
Why?
|
Physical Phenomena | 1 | 1999 | 48 | 0.010 |
Why?
|
United States | 2 | 2022 | 72363 | 0.010 |
Why?
|
Vascular Neoplasms | 1 | 2000 | 167 | 0.010 |
Why?
|
Neoplasms, Second Primary | 1 | 2006 | 1060 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2002 | 625 | 0.010 |
Why?
|
Microcomputers | 1 | 1998 | 141 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1630 | 0.010 |
Why?
|
Vena Cava, Inferior | 1 | 2000 | 458 | 0.010 |
Why?
|
Cisplatin | 1 | 2002 | 1642 | 0.010 |
Why?
|
Fundus Oculi | 1 | 1997 | 541 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2002 | 2945 | 0.010 |
Why?
|
Child, Preschool | 3 | 2008 | 42034 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2000 | 3618 | 0.010 |
Why?
|
Fluorescein Angiography | 1 | 1997 | 1045 | 0.010 |
Why?
|
Prospective Studies | 1 | 2016 | 54263 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2002 | 3491 | 0.010 |
Why?
|
Infant | 2 | 2008 | 36030 | 0.010 |
Why?
|
Child | 3 | 2008 | 79758 | 0.000 |
Why?
|
Posture | 1 | 1992 | 954 | 0.000 |
Why?
|
Kidney | 1 | 2000 | 7072 | 0.000 |
Why?
|
Liver | 1 | 2000 | 7512 | 0.000 |
Why?
|
Pneumonia | 1 | 1994 | 2138 | 0.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 11708 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 2002 | 13629 | 0.000 |
Why?
|
Risk Factors | 1 | 2003 | 74269 | 0.000 |
Why?
|